Cardiotoxicity, Leukemia, Lymphoid, Acute, Leukemia, Myeloid, Acute
Conditions
Brief summary
An observational, prospective study to describe the rates and predictors of cardiovascular events in patients with acute leukemia.
Detailed description
Patients recently diagnosed with acute leukemia and who will initiating chemotherapy will be enrolled and followed serially with blood collection, echocardiogram, arterial applanation tonometry, and questionnaires for 1 year.
Interventions
OTHERobservation only
No intervention, observational study only
Sponsors
Abramson Cancer Center at Penn Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Older than 18 years of age, * New diagnosis of untreated acute leukemia (prior treatment for myelodysplastic syndrome or myeloproliferative neoplams or prior treatment with an anthracycline for breast cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma or another diagnosis will be included). * Signed the informed consent form
Exclusion criteria
• Unable to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Left Ventricular dysfunction | 1 year | defined as a reduction in Left Ventricular Ejection Fraction of more than 10 percentage points from baseline and to less than 50%. |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Cardiovascular Events | 1 year |
| Incidence of Symptomatic Heart Failure | 1 year |
| Incidence of Cardiac Death and all mortality | 1 year |
Countries
United States
Outcome results
None listed